Actionable Mutations Impacting Breast Cancer Treatment
October 17th 2016Erin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.
Watch
An Overview of the MERIBEL Study in HER2-Negative Breast Cancer
October 13th 2016Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.
Watch
The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer
October 11th 2016Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
Watch
The Clinical Activity of Rucaparib in Patients With Ovarian Cancer
October 11th 2016Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.
Watch